Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to target tumors and lymphatic tissue. The firm's lead program, SON-1010 (IL-12-FHAB), is a single-chain version of human Interleukin 12 (IL-12), linked to the FHAB construct, for which pursuing clinical development in solid tumor indications, including ovarian cancer, soft tissue sarcoma, colorectal cancer, and breast cancer. Its SON-1210 (IL12-FHAB-IL15), is a bifunctional construct, combines FHAB with single-chain human IL-12 and human Interleukin 15 (IL-15). Its SON-080 is in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Industry: Pharmaceutical Preparations Peers: Benitec Biopharma Inc Cibus Inc CohBar, Inc. Ensysce Biosciences Inc Exicure Inc Xenetic Biosciences Inc NAVIDEA BIOPHARMACEUTICALS, INC. Phio Pharmaceuticals Corp Unicycive Therapeutics Inc